Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics

J.L. Corchero, B. Gasser, D. Resina, Wesley Smith, E. Parrilli, F. Vázquez, I. Abasolo, M. Giuliani, Jussi Jäntti, P. Ferrer, Markku Saloheimo, D. Mattanovich, S. Schwartz Jr, M.L. Tutino, A. Villaverde (Corresponding Author)

Research output: Contribution to journalReview ArticleScientificpeer-review

75 Citations (Scopus)

Abstract

Both conventional and innovative biomedical approaches require cost-effective protein drugs with high therapeutic potency, improved bioavailability, biocompatibility, stability and pharmacokinetics. The growing longevity of the human population, the increasing incidence and prevalence of age-related diseases and the better comprehension of genetic-linked disorders prompt to develop natural and engineered drugs addressed to fulfill emerging therapeutic demands. Conventional microbial systems have been for long time exploited to produce biotherapeutics, competing with animal cells due to easier operation and lower process costs. However, both biological platforms exhibit important drawbacks (mainly associated to intracellular retention of the product, lack of post-translational modifications and conformational stresses), that cannot be overcome through further strain optimization merely due to physiological constraints. The metabolic diversity among microorganisms offers a spectrum of unconventional hosts, that, being able to bypass some of these weaknesses, are under progressive incorporation into production pipelines. In this review we describe the main biological traits and potentials of emerging bacterial, yeast, fungal and microalgae systems, by comparing selected leading species with well established conventional organisms with a long run in protein drug production.
Original languageEnglish
Pages (from-to)140-153
Number of pages14
JournalBiotechnology Advances
Volume31
Issue number2
DOIs
Publication statusPublished - 2013
MoE publication typeA2 Review article in a scientific journal

Fingerprint

Costs and Cost Analysis
Pharmaceutical Preparations
Microalgae
Inborn Genetic Diseases
Proteins
Post Translational Protein Processing
Biological Availability
Therapeutics
Pharmacokinetics
Yeasts
Incidence
Population

Keywords

  • Aggregation
  • biotherapeutics
  • microbial cells
  • protein folding
  • protein production
  • recombinant protein

Cite this

Corchero, J. L., Gasser, B., Resina, D., Smith, W., Parrilli, E., Vázquez, F., ... Villaverde, A. (2013). Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics. Biotechnology Advances, 31(2), 140-153. https://doi.org/10.1016/j.biotechadv.2012.09.001
Corchero, J.L. ; Gasser, B. ; Resina, D. ; Smith, Wesley ; Parrilli, E. ; Vázquez, F. ; Abasolo, I. ; Giuliani, M. ; Jäntti, Jussi ; Ferrer, P. ; Saloheimo, Markku ; Mattanovich, D. ; Schwartz Jr, S. ; Tutino, M.L. ; Villaverde, A. / Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics. In: Biotechnology Advances. 2013 ; Vol. 31, No. 2. pp. 140-153.
@article{8325d722ed674768b2593990d6e0ec36,
title = "Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics",
abstract = "Both conventional and innovative biomedical approaches require cost-effective protein drugs with high therapeutic potency, improved bioavailability, biocompatibility, stability and pharmacokinetics. The growing longevity of the human population, the increasing incidence and prevalence of age-related diseases and the better comprehension of genetic-linked disorders prompt to develop natural and engineered drugs addressed to fulfill emerging therapeutic demands. Conventional microbial systems have been for long time exploited to produce biotherapeutics, competing with animal cells due to easier operation and lower process costs. However, both biological platforms exhibit important drawbacks (mainly associated to intracellular retention of the product, lack of post-translational modifications and conformational stresses), that cannot be overcome through further strain optimization merely due to physiological constraints. The metabolic diversity among microorganisms offers a spectrum of unconventional hosts, that, being able to bypass some of these weaknesses, are under progressive incorporation into production pipelines. In this review we describe the main biological traits and potentials of emerging bacterial, yeast, fungal and microalgae systems, by comparing selected leading species with well established conventional organisms with a long run in protein drug production.",
keywords = "Aggregation, biotherapeutics, microbial cells, protein folding, protein production, recombinant protein",
author = "J.L. Corchero and B. Gasser and D. Resina and Wesley Smith and E. Parrilli and F. V{\'a}zquez and I. Abasolo and M. Giuliani and Jussi J{\"a}ntti and P. Ferrer and Markku Saloheimo and D. Mattanovich and {Schwartz Jr}, S. and M.L. Tutino and A. Villaverde",
year = "2013",
doi = "10.1016/j.biotechadv.2012.09.001",
language = "English",
volume = "31",
pages = "140--153",
journal = "Biotechnology Advances",
issn = "0734-9750",
publisher = "Elsevier",
number = "2",

}

Corchero, JL, Gasser, B, Resina, D, Smith, W, Parrilli, E, Vázquez, F, Abasolo, I, Giuliani, M, Jäntti, J, Ferrer, P, Saloheimo, M, Mattanovich, D, Schwartz Jr, S, Tutino, ML & Villaverde, A 2013, 'Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics', Biotechnology Advances, vol. 31, no. 2, pp. 140-153. https://doi.org/10.1016/j.biotechadv.2012.09.001

Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics. / Corchero, J.L.; Gasser, B.; Resina, D.; Smith, Wesley; Parrilli, E.; Vázquez, F.; Abasolo, I.; Giuliani, M.; Jäntti, Jussi; Ferrer, P.; Saloheimo, Markku; Mattanovich, D.; Schwartz Jr, S.; Tutino, M.L.; Villaverde, A. (Corresponding Author).

In: Biotechnology Advances, Vol. 31, No. 2, 2013, p. 140-153.

Research output: Contribution to journalReview ArticleScientificpeer-review

TY - JOUR

T1 - Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics

AU - Corchero, J.L.

AU - Gasser, B.

AU - Resina, D.

AU - Smith, Wesley

AU - Parrilli, E.

AU - Vázquez, F.

AU - Abasolo, I.

AU - Giuliani, M.

AU - Jäntti, Jussi

AU - Ferrer, P.

AU - Saloheimo, Markku

AU - Mattanovich, D.

AU - Schwartz Jr, S.

AU - Tutino, M.L.

AU - Villaverde, A.

PY - 2013

Y1 - 2013

N2 - Both conventional and innovative biomedical approaches require cost-effective protein drugs with high therapeutic potency, improved bioavailability, biocompatibility, stability and pharmacokinetics. The growing longevity of the human population, the increasing incidence and prevalence of age-related diseases and the better comprehension of genetic-linked disorders prompt to develop natural and engineered drugs addressed to fulfill emerging therapeutic demands. Conventional microbial systems have been for long time exploited to produce biotherapeutics, competing with animal cells due to easier operation and lower process costs. However, both biological platforms exhibit important drawbacks (mainly associated to intracellular retention of the product, lack of post-translational modifications and conformational stresses), that cannot be overcome through further strain optimization merely due to physiological constraints. The metabolic diversity among microorganisms offers a spectrum of unconventional hosts, that, being able to bypass some of these weaknesses, are under progressive incorporation into production pipelines. In this review we describe the main biological traits and potentials of emerging bacterial, yeast, fungal and microalgae systems, by comparing selected leading species with well established conventional organisms with a long run in protein drug production.

AB - Both conventional and innovative biomedical approaches require cost-effective protein drugs with high therapeutic potency, improved bioavailability, biocompatibility, stability and pharmacokinetics. The growing longevity of the human population, the increasing incidence and prevalence of age-related diseases and the better comprehension of genetic-linked disorders prompt to develop natural and engineered drugs addressed to fulfill emerging therapeutic demands. Conventional microbial systems have been for long time exploited to produce biotherapeutics, competing with animal cells due to easier operation and lower process costs. However, both biological platforms exhibit important drawbacks (mainly associated to intracellular retention of the product, lack of post-translational modifications and conformational stresses), that cannot be overcome through further strain optimization merely due to physiological constraints. The metabolic diversity among microorganisms offers a spectrum of unconventional hosts, that, being able to bypass some of these weaknesses, are under progressive incorporation into production pipelines. In this review we describe the main biological traits and potentials of emerging bacterial, yeast, fungal and microalgae systems, by comparing selected leading species with well established conventional organisms with a long run in protein drug production.

KW - Aggregation

KW - biotherapeutics

KW - microbial cells

KW - protein folding

KW - protein production

KW - recombinant protein

U2 - 10.1016/j.biotechadv.2012.09.001

DO - 10.1016/j.biotechadv.2012.09.001

M3 - Review Article

VL - 31

SP - 140

EP - 153

JO - Biotechnology Advances

JF - Biotechnology Advances

SN - 0734-9750

IS - 2

ER -